DiaMedica Cleared for Phase 2 Trial of DM199 in Preeclampsia
Event summary
- DiaMedica received a No Objection Letter from Health Canada to initiate a Phase 2 trial of DM199 for early-onset preeclampsia.
- The open-label, dose-ranging study will evaluate safety, tolerability, and exploratory efficacy markers in pregnant women between 24 and 32 weeks gestation.
- Trial initiation is planned for 2026, with potential expansion into the U.S. and U.K. pending regulatory clearances.
The big picture
DiaMedica’s Phase 2 trial clearance for DM199 comes amid growing recognition of the urgent need for preeclampsia treatments, as highlighted by recent NPR coverage. The trial represents a strategic step in validating DM199’s potential to improve maternal outcomes, leveraging its mechanism to enhance arterial health and reduce blood pressure. Success could position DiaMedica as a key player in addressing this high-risk pregnancy complication.
What we're watching
- Regulatory Momentum
- Whether DiaMedica can secure timely approvals in the U.S. and U.K. to expand the Phase 2 trial beyond Canada.
- Clinical Efficacy
- How early markers of efficacy, such as changes in uterine artery pulsatility index and biomarkers, will influence future development decisions.
- Market Opportunity
- The pace at which DM199 could address the significant unmet medical need in preeclampsia, given no currently approved treatments exist.
Our editorial coverage:
Related topics